Compare Diamondback Energy Inc (FANG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Diamondback Energy Inc trades at $198 (market cap $55.49B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Diamondback Energy Inc is far larger — about 11.4× Travere Therapeutics Inc. Common Stock's market cap, and Diamondback Energy Inc pays a 2.22% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 70 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FANG | TVTX | |
|---|---|---|
Market Cap | $55.49B | $4.88B |
Volume | 2,752,760 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $213.69 | $67.52 |
52-Week Low | $137.29 | $26.79 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $67.65B | $5.01B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $197.51, up 1.23% with strong analyst support (90.57% buy rating) and a $232.54 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, while cash flow from operations improved to $8.76B in 2025. The stock shows bullish technical signals with support at $194 and resistance at $200, though RSI levels indicate potential overbought conditions.
FANG offers growth potential with rising revenue and operational efficiency, but faces risks from oil price volatility and declining profit margins. Institutional buying and positive Permian Basin developments support upside, while insider selling and competitive pressures warrant caution for investors seeking energy exposure.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
